NCT05102123

PeRiopEratiVE SmokiNg CessaTion Trial

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,720 (estimated)
• Sponsor: Population Health Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. This trial aims to investigate the effects of cytisine and text messaging on 6-month continuous abstinence rates. PREVENT will also assess secondary outcomes at 30 days, 56 days and 6 months post-randomization: 7-day point prevalence abstinence, urge to smoke, time to first lapse, time to relapse, number of cigarettes smoking if still smoking, pulmonary complications, vascular complications, wound and infectious complications, stroke, time in hospital and acute hospital care.

Conditions

• Smoking (Tobacco) Addiction
• Smoking Cessation

Interventions

Type	Name	Description
DRUG	Cytisine	Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
BEHAVIORAL	Video Messaging	Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.

Timeline

• Start date: 2024-01-15
• Primary completion: 2026-07-01
• Completion: 2027-01-01
• First posted: 2021-11-01
• Last updated: 2024-10-03

Locations

4 sites across 1 country: Canada